These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1988613)

  • 21. Assessment of antioxidative ability in brain: technetium-99m-meso-HMPAO as an imaging agent for glutathione localization.
    Sasaki T; Toyama H; Oda K; Ogihara-Umeda I; Nishigori H; Senda M
    J Nucl Med; 1996 Oct; 37(10):1698-701. PubMed ID: 8862315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative study of the structure-stability relationship of TcvO(III) complexes.
    Kung HF; Liu BL; Wei Y; Pan S
    Int J Rad Appl Instrum A; 1990; 41(8):773-81. PubMed ID: 2172189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Technetium-99m HM-PAO stereoisomers: differences in interaction with glutathione.
    Ballinger JR; Reid RH; Gulenchyn KY
    J Nucl Med; 1988 Dec; 29(12):1998-2000. PubMed ID: 3193211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiochemical purity of 99mTc-HM-PAO: critical parameters during kit preparation.
    Seifert S; Muth O; Jantsch K; Johannsen B
    Nucl Med Biol; 1995 Nov; 22(8):1063-6. PubMed ID: 8998468
    [No Abstract]   [Full Text] [Related]  

  • 25. Lacrimal gland dosimetry for the brain imaging agent technetium-99m-HMPAO.
    Villanueva-Meyer J; Thompson D; Mena I; Marcus CS
    J Nucl Med; 1990 Jul; 31(7):1237-9. PubMed ID: 2362204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stabilization of [99mTc]HMPAO--1. Ethanolic preparation.
    Billinghurst MW; Abrams DN; Lawson MS
    Int J Rad Appl Instrum A; 1991; 42(7):607-12. PubMed ID: 1663094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purification and stabilization of 99mTc-d,l-HMPAO: role of organic extractants.
    Chattopadhyay S; Das MK; Vanaja R; Ramamoorthy N
    Nucl Med Biol; 2001 Aug; 28(6):741-4. PubMed ID: 11518658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the synthesis, isolation, and radiochemical studies for the preparation of in-house kits for 99mTc-meso- and d,l-HMPAO: a few additional observations.
    Banerjee S; Samuel G; Kothari K; Sarma HD; Pillai MR
    Nucl Med Biol; 1999 Apr; 26(3):327-38. PubMed ID: 10363805
    [No Abstract]   [Full Text] [Related]  

  • 29. Technetium-99m-meso-HMPAO as a potential agent to image cerebral glutathione content.
    Sasaki T; Senda M
    J Nucl Med; 1997 Jul; 38(7):1125-9. PubMed ID: 9225804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the arterial input curve for [99mTc]-d,l-HM-PAO by rapid octanol extraction.
    Andersen AR; Friberg H; Lassen NA; Kristensen K; Neirinckx RD
    J Cereb Blood Flow Metab; 1988 Dec; 8(6):S23-30. PubMed ID: 3192639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Stabilization of 99m Tc-HMPAO with methylene blue: its use in leukocyte labelling)].
    García Seguí V; Roca Engroñat M; Armero Muñoz F; Iglesias Allende F; Gomes Barreto de Mélo V; Martin-Comín J
    Rev Esp Med Nucl; 1998; 17(4):261-4. PubMed ID: 9721341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparation of technetium-99m-HMPAO.
    Ballinger J
    J Nucl Med; 1990 Nov; 31(11):1892. PubMed ID: 2231007
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparison of three methods to determine the radiochemical purity of 99Tcm-hexamethylpropylene amine oxime (99Tcm-HMPAO).
    Mah G; Reilly RM; Wong GL; Houle S
    Nucl Med Commun; 1989 Oct; 10(10):733-40. PubMed ID: 2616098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Miniaturized Radiochemical Purity Testing for
    Fuente A; Zanca R; Boni R; Cataldi AG; Sollini M; Lazzeri E; Mariani G; Erba PA
    J Nucl Med Technol; 2017 Sep; 45(3):236-240. PubMed ID: 28705928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of 99Tcm-d,l-HMPAO and 99Tcm-d,l-CBPAO as leukocyte-labelling agents.
    Tsai CS; Kao CH; Yeh SJ; Wang SJ
    Nucl Med Commun; 1996 Jan; 17(1):76-9. PubMed ID: 8692477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiochemical purity of D,L-hexamethylpropylene amine oxime and analysis of urine-excreted HMPAO decomposition species.
    Ivancević V; Kuster Z; Mastrović Z; Ivancević D
    Eur J Nucl Med; 1990; 17(1-2):34-7. PubMed ID: 2083541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of technetium-99m exametazime stabilised with cobalt chloride as a blood flow tracer in focal cerebral ischaemia.
    Gartshore G; Bannan P; Patterson J; Higley B; McCulloch J
    Eur J Nucl Med; 1994 Sep; 21(9):913-23. PubMed ID: 7995284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An efficient HPLC method for the analysis of isomeric purity of technetium-99m-exametazime and identity confirmation using LC-MS.
    Vanderghinste D; Van Eeckhoudt M; Terwinghe C; Mortelmans L; Bormans GM; Verbruggen AM; Vanbilloen HP
    J Pharm Biomed Anal; 2003 Aug; 32(4-5):679-85. PubMed ID: 12899958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Procedure for red blood cell labelling with 99mTc-HMPAO. Methodology and quality control.
    Bassa P; García Garzón JR; Piera C; Pavía A; Minoves M; Moragas M; Pavía J; Lomeña F; Setoain J
    Nucl Med Biol; 1994 Oct; 21(7):963-7. PubMed ID: 9234351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technetium-99m exametazime (99mTc-HMPAO)-labeled white blood cells: a high efficiency multidose procedure.
    Ozker K; Collier BD; Hellman RS; Isitman AT; Uzum F; Steffel FG
    Eur J Nucl Med; 1995 Feb; 22(2):182-3. PubMed ID: 7758507
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.